Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H, Murphy C, Morgan R, Morash C, Parulekar W, Parmar M, Savage C, Stansfeld J, Sydes M; RADICALS Trial Management Group. Parker C, et al. Among authors: clarke n. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):167-71. doi: 10.1016/j.clon.2007.01.001. Epub 2007 Feb 7. Clin Oncol (R Coll Radiol). 2007. PMID: 17359901 Clinical Trial. No abstract available.
Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.
Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, Morgan RC, Mellon K, Morash C, Parulekar W, Parmar MK, Payne H, Savage C, Stansfeld J, Clarke NW; (RADICALS Trial Management Group). Parker C, et al. BJU Int. 2007 Jun;99(6):1376-9. doi: 10.1111/j.1464-410X.2007.06844.x. Epub 2007 Apr 8. BJU Int. 2007. PMID: 17428247 Clinical Trial. No abstract available.
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.
Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P, Kockelbergh R, Lalani el-N, Dearnaley D, Parmar M, Abel PD. Langley RE, et al. Among authors: clarke nw. BJU Int. 2008 Aug;102(4):442-5. doi: 10.1111/j.1464-410X.2008.07583.x. Epub 2008 Apr 16. BJU Int. 2008. PMID: 18422771 Free PMC article. Clinical Trial.
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. James ND, et al. Among authors: clarke nw. Lancet Oncol. 2012 May;13(5):549-58. doi: 10.1016/S1470-2045(12)70088-8. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452894 Free PMC article. Clinical Trial.
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.
Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Ritchie AW, Russell JM, Thalmann G, Parmar MK, James ND. Parker CC, et al. BJU Int. 2013 May;111(5):697-9. doi: 10.1111/bju.12087. BJU Int. 2013. PMID: 23578233 Review. No abstract available.
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND. Attard G, et al. Eur Urol. 2014 Nov;66(5):799-802. doi: 10.1016/j.eururo.2014.05.038. Epub 2014 Jun 27. Eur Urol. 2014. PMID: 24985962 Free article. Clinical Trial.
1,454 results